1 study found for:    NCT00026312
Show Display Options
Rank Status Study
1 Active, not recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: Aldesleukin;   Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Sargramostim

Indicates status has not been verified in more than two years